<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03792737</url>
  </required_header>
  <id_info>
    <org_study_id>ESC-201702</org_study_id>
    <nct_id>NCT03792737</nct_id>
  </id_info>
  <brief_title>A Study of Two Types of Absorbable Surgical Sutures in the Suturing of Thyroid Surgery Incision</brief_title>
  <acronym>Nautilus</acronym>
  <official_title>A Prospective, Multi-center, Randomized Controlled Study Evaluating the Efficacy and Safety of Two Types of Absorbable Surgical Sutures in the Suturing of Thyroid Surgery Incision</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ethicon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ethicon, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy and safety of two types of&#xD;
      absorbable surgical sutures -- STRATAFIX Spiral PDS Knotless Plus Tissue Control Device and&#xD;
      STRATAFIX Spiral MONOCRYL Plus Knotless Tissue Control Device (hereinafter referred to as&#xD;
      Spiral PDS Plus and Spiral MONOCRYL Plus) used in thyroid surgery to suture surgical&#xD;
      incision.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study adopts a multicenter, prospective, randomized controlled design. The study&#xD;
      population are subjects who undergo thyroid surgery.&#xD;
&#xD;
      Before the surgery, subjects are randomized in 1:1:1 ratio to the investigational group 1&#xD;
      (using Spiral PDS Plus), investigational group 2 (using Spiral MONOCRYL Plus) and control&#xD;
      group. See the table below for the specific suture levels, materials and techniques of each&#xD;
      group.&#xD;
&#xD;
      A blinded central imaging evaluation will be performed on the healing condition of surgical&#xD;
      incision on Day 5-7 post-surgery. The subjects will be blinded to the type of suture used for&#xD;
      wound closure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Actual">January 6, 2020</completion_date>
  <primary_completion_date type="Actual">December 12, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound Healing Grade</measure>
    <time_frame>5-7days</time_frame>
    <description>Percentage of Participants with Grade A Healing of Surgical Incision</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">501</enrollment>
  <condition>Sutures</condition>
  <arm_group>
    <arm_group_label>Investigational group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational group 1: Use the study device Spiral PDS Plus for continuous suture of the ribbon muscles, VICRYL Plus for interrupted suture of the platysma, and MONOCRYL Plus for continuous subcuticular suture.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational group 2: Use PDS Plus for continuous suture of the ribbon muscles, VICRYL Plus for interrupted suture of the platysma, and the study device Spiral MONOCRYL Plus for continuous subcuticular suture.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group: Use the control device PDS Plus for continuous suture of the ribbon muscles, VICRYL Plus for interrupted suture of the platysma, and the control device MONOCRYL Plus continuous subcuticular suture.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spiral PDS Plus</intervention_name>
    <description>The Spiral PDS Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral PDS Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.</description>
    <arm_group_label>Investigational group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spiral MONOCRYL Plus</intervention_name>
    <description>The Spiral MONOCRYL Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral MONOCRYL Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.</description>
    <arm_group_label>Investigational group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PDS Plus</intervention_name>
    <description>PDS Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Investigational group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MONOCRYL Plus</intervention_name>
    <description>MONOCRYL Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Investigational group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VICRYL Plus</intervention_name>
    <description>VICRYL Plus antibacterial suture is a non-barbed synthetic absorbable sterile, surgical suture. The suture contains triclosan, a broad spectrum antibacterial agent.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Investigational group 1</arm_group_label>
    <arm_group_label>Investigational group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject is ≥18, and &lt;70 years old&#xD;
&#xD;
          2. Planned open thyroid surgery, adopting an anterior cervical curved incision (Kocher's&#xD;
             incision);&#xD;
&#xD;
          3. Subject who volunteers to participate in this study, follows the study requirements&#xD;
             and follow-up visit and signs the written Informed Consent Form voluntarily;&#xD;
&#xD;
          4. Subject who agrees to not schedule any elective surgical operation except the study&#xD;
             surgery before the study is completed;&#xD;
&#xD;
          5. The investigator considers the subject's expected postoperative survival time is not&#xD;
             less than 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female subjects who are pregnant or lactation at screening;&#xD;
&#xD;
          2. Preoperative clinical staging shows stage IV thyroid cancer, or cervical lymph nodes&#xD;
             dissection is planned;&#xD;
&#xD;
          3. Suspected or confirmed anaplastic thyroid cancer;&#xD;
&#xD;
          4. Peripheral vascular disease affecting blood supply of the neck;&#xD;
&#xD;
          5. Active infectious collagenosis (e.g. scleroderma), or any other disease that would&#xD;
             interfere with wound healing;&#xD;
&#xD;
          6. Fasting plasma glucose ≥7.7 mmol/L;&#xD;
&#xD;
          7. History of coagulation diseases;&#xD;
&#xD;
          8. Current oral or intravenous antibiotic therapy for existing disease or infection;&#xD;
&#xD;
          9. History of immunosuppressant use (e.g. steroids) within the last 6 months;&#xD;
&#xD;
         10. Chemotherapy or radiotherapy within the last 6 months, or planned chemotherapy or&#xD;
             radiotherapy during the study;&#xD;
&#xD;
         11. Personal or family history of keloid formation or hyperplasia;&#xD;
&#xD;
         12. Current participation in any other drug (within 30 days or within 5 half-lives of the&#xD;
             investigational drug) or device clinical study;&#xD;
&#xD;
         13. History of any thyroid surgery, except thyroid fine-needle aspiration biopsy;&#xD;
&#xD;
         14. Planned use of skin adhesive at the incision site;&#xD;
&#xD;
         15. The subject is not suitable for participating in this study for any other reasons, as&#xD;
             judged by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hao Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Hospital of China Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Shenzhen Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518035</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital Tongji Medical college Huazhong University of science and technologyUnion Hospital Tongji Medical college Huazhong University of science and technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'An Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sicuan Province</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 29, 2018</study_first_submitted>
  <study_first_submitted_qc>January 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2019</study_first_posted>
  <results_first_submitted>December 11, 2020</results_first_submitted>
  <results_first_submitted_qc>January 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 29, 2021</results_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 23, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT03792737/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 30, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT03792737/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>one subject didn't participate screen visit and randomize, but receive IP(group 2) treatment by mistake. investigator collect his safety information. so in protocol enrollment plan is 501 subjects, but actually received screen and randomization is 500 patients.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Investigational Group 1</title>
          <description>Spiral PDS Plus</description>
        </group>
        <group group_id="P2">
          <title>Investigational Group 2</title>
          <description>Spiral MONOCRYL Plus</description>
        </group>
        <group group_id="P3">
          <title>Control groupEdit</title>
          <description>PDS Plus or Monocryl Plus</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="167"/>
                <participants group_id="P3" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="161">one subject didn't participate screen visit or randomize, but receive IP treatment by mistake.</participants>
                <participants group_id="P3" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="160"/>
                <participants group_id="P3" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="159"/>
                <participants group_id="P3" count="158"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Population(FAS): FAS consists of all the enrolled subjects who were randomized and at least post-baseline effectiveness endpoint evaluation.</population>
      <group_list>
        <group group_id="B1">
          <title>Investigational Group 1</title>
          <description>Spiral PDS Plus</description>
        </group>
        <group group_id="B2">
          <title>Investigational Group 2</title>
          <description>Spiral MONOCRYL Plus</description>
        </group>
        <group group_id="B3">
          <title>Control groupEdit</title>
          <description>PDS Plus or Monocryl Plus</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="162"/>
            <count group_id="B2" value="160"/>
            <count group_id="B3" value="162"/>
            <count group_id="B4" value="484"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.1" spread="10.66"/>
                    <measurement group_id="B2" value="41.2" spread="10.84"/>
                    <measurement group_id="B3" value="40.3" spread="11.32"/>
                    <measurement group_id="B4" value="40.5" spread="10.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="111"/>
                    <measurement group_id="B4" value="336"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Han</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="155"/>
                    <measurement group_id="B4" value="470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Wound Healing Grade</title>
        <description>Percentage of Participants with Grade A Healing of Surgical Incision</description>
        <time_frame>5-7days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Investigational group1</title>
            <description>Spiral PDS Plus</description>
          </group>
          <group group_id="O2">
            <title>Investigational group2</title>
            <description>Spiral MONOCRYL Plus</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>PDS Plus or Monocryl Plus</description>
          </group>
        </group_list>
        <measure>
          <title>Wound Healing Grade</title>
          <description>Percentage of Participants with Grade A Healing of Surgical Incision</description>
          <units>percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.35" lower_limit="96.44" upper_limit="99.98"/>
                    <measurement group_id="O2" value="98.73" lower_limit="95.47" upper_limit="99.85"/>
                    <measurement group_id="O3" value="99.36" lower_limit="96.48" upper_limit="99.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>35 days</time_frame>
      <desc>AE is an untoward medical occurrence during the clinical study and which does not necessarily have a causal relationship with the study medical device.&#xD;
one subject didn't participate screen visit and randomize, but receive IP(group 2) treatment by mistake. investigator collect his safety information. so the Number of Participants at Risk of group 2 is one more than other rows.</desc>
      <group_list>
        <group group_id="E1">
          <title>Investigational Group 1</title>
          <description>Spiral PDS Plus</description>
        </group>
        <group group_id="E2">
          <title>Investigational Group 2</title>
          <description>Spiral MONOCRYL Plus</description>
        </group>
        <group group_id="E3">
          <title>Control groupEdit</title>
          <description>PDS Plus or Monocryl Plus</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>study protocol</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Breast adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Metastatic lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>study protocol</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="162"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="161"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="162"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="161"/>
                <counts group_id="E3" events="31" subjects_affected="31" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="28" subjects_affected="27" subjects_at_risk="162"/>
                <counts group_id="E2" events="26" subjects_affected="25" subjects_at_risk="161"/>
                <counts group_id="E3" events="29" subjects_affected="29" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The disclosure restriction on the principal investigator(PI) is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Xiaolei, Wang</name_or_title>
      <organization>Johnson &amp; Johnson Medical Shanghai Ltd.</organization>
      <phone>+86 21 33378749</phone>
      <email>xwang183@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

